Effectiveness of a 10-Valent Pneumococcal Vaccine in Finland

A 10-valent pneumococcal conjugate vaccine was very effective, whether given as two or three doses plus booster, in infants aged <7 months.

The first pneumococcal conjugate vaccine (Prevnar 7; Pfizer) contained the antigens of seven serotypes. Approved by the FDA in 2000, it has since been superseded by the 13-antigen Prevnar 13. PHiD-CV10 — a 10-valent pneumococcal conjugate vaccine in which the 10 polysaccharides are conjugated to Haemophilus influenzae protein D, tetanus toxoid, and diphtheria toxoid as the carrier proteins — was licensed in the European Union in March 2009 (Synflorix; GlaxoSmithKline) and is available in many countries. In a recent manufacturer-sponsored, cluster-randomized trial, investigators in Finland examined the effectiveness of PHiD-CV10, administered in various schedules, against invasive pneumococcal disease (IPI).

A total of 45,977 children from 13…

Reviewing Author

Robert S. Baltimore, MD

Disclosures

Editorial BoardsInfectious Diseases in Children

Leadership Positions in Professional SocietiesMember Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease

Robert S. Baltimore, MD

Disclosures

Editorial BoardsInfectious Diseases in Children

Leadership Positions in Professional SocietiesMember Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease

Effectiveness of a 10-Valent Pneumococcal Vaccine in Finland

Topics

Reviewing Author